Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3550441 | 0.90 | USP2 (0.46) | USP2AVPR2ALDH1A1LMNATSHR | |
| SCHEMBL3553322 | 0.89 | POLB (0.48) | USP2AVPR2ALDH1A1LMNATSHR | |
| SCHEMBL3554592 | 0.88 | NAMPT (0.52) | AVPR2ALDH1A1LMNAHPGDHTT | |
| SCHEMBL3554440 | 0.88 | USP2 (0.47) | USP2ALDH1A1LMNATSHRHPGD | |
| SCHEMBL3550414 | 0.88 | STAT3 (0.48) | USP2ALDH1A1LMNATSHRHPGD | |
| SCHEMBL3556503 | 0.87 | USP2 (0.44) | USP2AVPR2ALDH1A1LMNATSHR | |
| SCHEMBL3553283 | 0.87 | AVPR1A (0.44) | AVPR2ALDH1A1LMNATSHRHPGD | |
| SCHEMBL3556720 | 0.87 | AVPR1A (0.51) | AVPR2ALDH1A1LMNATSHRHTT | |
| SCHEMBL3558000 | 0.87 | HTT (0.54) | USP2ALDH1A1LMNATSHRHPGD | |
| SCHEMBL3553868 | 0.87 | POLB (0.48) | USP2ALDH1A1LMNATSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678787-B2 | Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists | WYETH (US) | 2010-03-16 | — | — | US | claimed |
| EP-1893615-A1 | PYRROLOBENZODIAZEPINE PYRIDINE CARBOXAMIDES AND DERIVATIVES AS FOLLICLE-STIMULATING HORMONE RECEPTOR ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2008-03-05 | — | — | EP | claimed |
| US-20060287522-A1 | Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists | WYETH (US) | 2006-12-21 | — | — | US | claimed |
| WO-2006135687-A1 | PYRROLOBENZODIAZEPINE PYRIDINE CARBOXAMIDES AND DERIVATIVES AS FOLLICLE-STIMULATING HORMONE RECEPTOR ANTAGONISTS | WYETH (US) | 2006-12-21 | — | — | WO | claimed |
| US-7678787-B2 | Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists | WYETH (US) | 2010-03-16 | — | — | US | disclosed |
| US-20060287522-A1 | Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists | WYETH (US) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287522-A1 | Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists | FSHR, GNRHR, PRLHR | USP2 2723/4885AVPR2 26/4885ALDH1A1 4219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.